GlassScriptPhysician profile
Melissa Spears
NPI 1790911469
$11,842.44
in general payments reported to CMS, 2019-2025
24 companies · $4,100 in 2025
The $4,100 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.76 · 2022: $236 · 2023: $2,826 · 2024: $4,628 · 2025: $4,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,025 · Travel and Lodging: $2,481 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,024.54 |
| Travel and Lodging | $2,481.03 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,942.54 | 2023-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,502.69 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $985.14 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $751.95 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $749.96 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $655.61 | 2022-2025 | Ingrezza |
| Corium, LLC | $569.03 | 2022-2025 | Azstarys |
| Lundbeck LLC | $475.86 | 2022-2025 | Rexulti |
| Tris Pharma INC | $358.90 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $345.50 | 2024-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $258.67 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Almatica Pharma LLC | $205.61 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $193.68 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $183.79 | 2022-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $181.65 | 2022-2024 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $125.04 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $117.80 | 2024-2025 | Keytruda, Welireg |
| Noven Therapeutics, LLC | $70.51 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $58.36 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| E.R. Squibb & Sons, L.L.C. | $37.58 | 2023-2024 | Opdivo, Cobenfy |
| Indivior INC. | $23.30 | 2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $20.74 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.28 | 2025 | |
| Braeburn INC. | $14.25 | 2025 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.